Company intelligence / Profile preview

Destiny Pharma

Brighton, England, United Kingdomdestinypharma.com ↗

Ownership: Private
Employees: ~15
Development stage: Phase 3

Overview

Destiny Pharma has two late-stage clinical programs. The lead asset, XF‑73 Nasal Gel, achieved its primary endpoint in a Phase IIb trial by reducing nasal S. aureus bacterial load by over 99% compared to placebo with an excellent safety profile and no treatment-related adverse events. However, the company has struggled to secure a partner or funding for Phase III trials due to high anticipated costs and market challenges for antibiotics. Its second late-stage asset, NTCD-M3—a microbiome therapeutic—targets prevention of C. difficile infection recurrence.

Therapeutic areas: Infectious Diseases
Modalities: Small molecules (e.g., XF platform synthetic porphyrins)Microbiome-based biotherapeutics (e.g., NTCD-M3)
Industry: Biotech

Drug pipeline

3 assets

XF-73 Nasal

Phase 3

Indications: Post-surgical Staphylococcal infections

2 more assets in the full pipeline.

Partnerships

CMS China partnership for development/commercialization in China regionseeking additional partners globally

Beyond the preview

Go deeper on Destiny Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Destiny Pharma.